Jeffrey Kent

Jeffrey Kent

Horizon Therapeutics - / United States
Others
AD Scientific Index ID: 4964447
person_outline Jeffrey Kent's MOST POPULAR ARTICLES
1-) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial FE Silverstein, G Faich, JL Goldstein, LS Simon, T Pincus, A Whelton, ... Jama 284 (10), 1247-1255, 2000 43452000
2-) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial JF Colombel, WJ Sandborn, P Rutgeerts, R Enns, SB Hanauer, ... Gastroenterology 132 (1), 52-65, 2007 25682007
3-) Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial WJ Sandborn, SB Hanauer, P Rutgeerts, RN Fedorak, M Lukas, ... Gut 56 (9), 1232-1239, 2007 12172007
4-) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialWJ Sandborn, P Rutgeerts, R Enns, SB Hanauer, JF Colombel, ...Annals of internal medicine 146 (12), 829-838, 200712822007
5-) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisMH Schiff, GR Burmester, JD Kent, AL Pangan, H Kupper, SB Fitzpatrick, ...Annals of the rheumatic diseases 65 (7), 889-894, 20064922006